Evoke Pharma (NASDAQ:EVOK) Stock Price Crosses Below 200 Day Moving Average – Here’s Why

Posted by Kyle Jackson on Mar 29th, 2025

Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report)’s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $4.64 and traded as low as $2.66. Evoke Pharma shares last traded at $2.79, with a volume of 11,492 shares changing hands.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Evoke Pharma in a research note on Friday. They issued a “sell” rating for the company.

View Our Latest Stock Report on Evoke Pharma

Evoke Pharma Stock Performance

The firm has a market capitalization of $4.17 million, a PE ratio of -0.25 and a beta of 0.12. The business’s fifty day simple moving average is $4.25 and its 200-day simple moving average is $4.63.

Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The company had revenue of $3.31 million during the quarter, compared to the consensus estimate of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Institutional Investors Weigh In On Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC raised its position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) by 163.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after acquiring an additional 91,945 shares during the period. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Evoke Pharma Company Profile

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.